Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
J Eur Acad Dermatol Venereol. 2015.
PMID: 24661317
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2004 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 31 |
| 2013 | 35 |
| 2014 | 43 |
| 2015 | 40 |
| 2016 | 47 |
| 2017 | 35 |
| 2018 | 23 |
| 2019 | 28 |
| 2020 | 25 |
| 2021 | 23 |
| 2022 | 22 |
| 2023 | 20 |
| 2024 | 7 |
| 2025 | 13 |
| 2026 | 10 |
Search Results
355 results
Results by year
Citations
2
articles
found by citation matching
Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.
Am J Clin Dermatol. 2013.
PMID: 24048637
Review.
Search results
Page 1
Melanoma.
Lancet. 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9.
Lancet. 2018.
PMID: 30238891
Review.
Cutaneous melanoma causes 55 500 deaths annually. The incidence and mortality rates of the disease differ widely across the globe depending on access to early detection and primary care. ...Treatments that target B-Raf proto-oncogene serine/threonine-kinase (BRAF)(V …
Cutaneous melanoma causes 55 500 deaths annually. The incidence and mortality rates of the disease differ widely across the globe dep …
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management.
ESMO Open. 2019 May 23;4(3):e000491. doi: 10.1136/esmoopen-2019-000491. eCollection 2019.
ESMO Open. 2019.
PMID: 31231568
Free PMC article.
Review.
The inhibition of the mitogen-activated protein kinases signalling pathway through combined use of BRAF and MEK inhibitors (BRAFi+MEKi) represents an established therapeutic option in patients with BRAF-mutated, advanced melanoma. ...Based on data from confir …
The inhibition of the mitogen-activated protein kinases signalling pathway through combined use of BRAF and MEK inhibitors (BR …
Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.
Curr Treat Options Oncol. 2020 Mar 19;21(4):29. doi: 10.1007/s11864-020-0721-7.
Curr Treat Options Oncol. 2020.
PMID: 32193712
Review.
This transition from cytotoxic chemotherapy has yielded improvements in both survival and quality of life; yet despite their therapeutic advantages, these treatments have been associated with a diverse range of cutaneous adverse events (AEs). These range from relati …
This transition from cytotoxic chemotherapy has yielded improvements in both survival and quality of life; yet despite their therapeutic adv …
Cutaneous melanoma.
Nat Rev Dis Primers. 2025 Apr 3;11(1):23. doi: 10.1038/s41572-025-00603-8.
Nat Rev Dis Primers. 2025.
PMID: 40180935
Review.
Cutaneous melanoma is a common cancer in Australia and New Zealand, Europe, and North America, and its incidence is still increasing in many regions. ...Cutaneous melanoma treatment has improved considerably over the past decade with the discovery and development of …
Cutaneous melanoma is a common cancer in Australia and New Zealand, Europe, and North America, and its incidence is still increasing …
Cutaneous Melanoma: A Review.
JAMA. 2025 Dec 16;334(23):2113-2125. doi: 10.1001/jama.2025.13074.
JAMA. 2025.
PMID: 40853557
Review.
For stage III disease, recurrence risk is decreased with nivolumab (HR, 0.72 [95% CI, 0.60-0.86]), pembrolizumab (HR, 0.61 [95% CI, 0.51-0.72]), or BRAF + MEK inhibitor therapy (dabrafenib + trametinib) (HR, 0.52 [95% CI, 0.43-0.63]). ...For stage III melanoma, anti …
For stage III disease, recurrence risk is decreased with nivolumab (HR, 0.72 [95% CI, 0.60-0.86]), pembrolizumab (HR, 0.61 [95% CI, 0.51-0.7 …
Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature.
Dermatol Res Pract. 2016;2016:5361569. doi: 10.1155/2016/5361569. Epub 2016 Mar 3.
Dermatol Res Pract. 2016.
PMID: 27042173
Free PMC article.
Review.
However, some adverse reactions have been reported in patients in the course of treatment. Cutaneous side effects are the most common adverse events among them with a broad spectrum. Both the case reports and several original clinical trials reported …
However, some adverse reactions have been reported in patients in the course of treatment. Cutaneous side effects are t …
Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
J Am Acad Dermatol. 2015 Feb;72(2):221-36; quiz 237-8. doi: 10.1016/j.jaad.2014.07.033.
J Am Acad Dermatol. 2015.
PMID: 25592339
Review.
Along with skin cancer, deregulation of the PI3K-AKT-mTOR and RAS-RAF-MEK-ERK intracellular signaling pathways contributes to tumorigenesis of a multitude of other cancers, and inhibitors of these pathways are being actively studied. Similar to other classes of targeted th …
Along with skin cancer, deregulation of the PI3K-AKT-mTOR and RAS-RAF-MEK-ERK intracellular signaling pathways contributes to tumorigenesis …
Improved overall survival in melanoma with combined dabrafenib and trametinib.
N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
N Engl J Med. 2015.
PMID: 25399551
Free article.
Clinical Trial.
BACKGROUND: The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. ...The objective response rate was 64% in the combination-therapy gro …
BACKGROUND: The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously un …
Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.
Am J Clin Dermatol. 2013 Dec;14(6):461-71. doi: 10.1007/s40257-013-0045-5.
Am J Clin Dermatol. 2013.
PMID: 24048637
Review.
However, cutaneous adverse effects-from proliferative processes to more classic drug side effects-are increasingly being reported in patients on BRAF inhibitors. In this comprehensive literature review we provide (1) an all-inclusive list …
However, cutaneous adverse effects-from proliferative processes to more classic drug side effects-are increasing …
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.
N Engl J Med. 2017.
PMID: 28891408
Free article.
Clinical Trial.
BACKGROUND: Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. ...CONCLUSIONS: Adjuvant use of combination therapy with dabrafenib plus …
BACKGROUND: Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival …
Cite